A

Arecor Therapeutics PLC
LSE:AREC

Watchlist Manager
Arecor Therapeutics PLC
LSE:AREC
Watchlist
Price: 78 GBX 5.41% Market Closed
Market Cap: 29.5m GBX

Arecor Therapeutics PLC
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Arecor Therapeutics PLC
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
A
Arecor Therapeutics PLC
LSE:AREC
Income from Continuing Operations
-ÂŁ10.2m
CAGR 3-Years
-18%
CAGR 5-Years
-52%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Income from Continuing Operations
-$235.8m
CAGR 3-Years
15%
CAGR 5-Years
-116%
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Income from Continuing Operations
-$250.7m
CAGR 3-Years
-35%
CAGR 5-Years
-46%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Income from Continuing Operations
-ÂŁ51.1m
CAGR 3-Years
27%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Income from Continuing Operations
ÂŁ19.3m
CAGR 3-Years
-19%
CAGR 5-Years
-12%
CAGR 10-Years
-7%
Oxford BioMedica PLC
LSE:OXB
Income from Continuing Operations
-ÂŁ39.1m
CAGR 3-Years
-14%
CAGR 5-Years
-25%
CAGR 10-Years
-15%
No Stocks Found

Arecor Therapeutics PLC
Glance View

Market Cap
29.5m GBX
Industry
Biotechnology

Arecor Therapeutics Plc is a biopharmaceutical company that targets improving patient care by bringing medicines to market through the enhancement of existing therapeutic products. The firm targets improving patient care by bringing medicines to market through the existing therapeutic products. The company partners with global pharmaceutical and biotechnology companies to apply the Arestat technology to their products under a technology licensing model. These products can be at any stage in development from early phase clinical development through to products that are already on the market. The areas of applications of the technology are biologicals, biosimilars, therapeutic vaccines and therapeutic peptides.

AREC Intrinsic Value
20.08 GBX
Overvaluation 74%
Intrinsic Value
Price
A

See Also

What is Arecor Therapeutics PLC's Income from Continuing Operations?
Income from Continuing Operations
-10.2m GBP

Based on the financial report for Dec 31, 2024, Arecor Therapeutics PLC's Income from Continuing Operations amounts to -10.2m GBP.

What is Arecor Therapeutics PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-52%

Over the last year, the Income from Continuing Operations growth was -20%. The average annual Income from Continuing Operations growth rates for Arecor Therapeutics PLC have been -18% over the past three years , -52% over the past five years .

Back to Top